# W. Carter Neild, CFA
W. Carter Neild, CFA is a healthcare investor who serves as a Managing Partner of OrbiMed, a global healthcare-focused investment firm, where he has worked since 2002 and led the firm's expansion into healthcare royalties and Asia private investments.[1](https://www.orbimed.com/leadership/w-carter-neild-cfa/) A University of Chicago M.B.A. and chartered financial analyst, he previously held roles at UBS Alternative Investments and First Chicago's investment management division.[1](https://www.orbimed.com/leadership/w-carter-neild-cfa/)
| | |
|---|---|
| **Role** | Managing Partner, OrbiMed (joined 2002)[1](https://www.orbimed.com/leadership/w-carter-neild-cfa/) |
| **Firm profile** | OrbiMed, described by the University of Chicago Polsky Center as a $17 billion global healthcare-focused private investment firm[2](https://polsky.uchicago.edu/people/carter-neild/) |
| **Prior firms** | Director, UBS Alternative Investments Group; four years in the investment management division of First Chicago (now part of J.P. Morgan)[1](https://www.orbimed.com/leadership/w-carter-neild-cfa/) |
| **Education** | M.B.A. in Finance, University of Chicago (MBA '97); B.A. in Economics, Emory University; C.E.P., Institut d'Etudes Politiques, Paris, 1991[1](https://www.orbimed.com/leadership/w-carter-neild-cfa/) • [2](https://polsky.uchicago.edu/people/carter-neild/) |
| **CFA charter** | Awarded 1995[1](https://www.orbimed.com/leadership/w-carter-neild-cfa/) |
| **Councils** | Rockefeller University Council; University of Chicago Booth Private Equity Council; Harper Society[1](https://www.orbimed.com/leadership/w-carter-neild-cfa/) • [2](https://polsky.uchicago.edu/people/carter-neild/) |
## Education and early career
Neild received a B.A. in [Economics](https://www.edgepedia.org/economics) from [Emory University](https://www.edgepedia.org/emory-university), where he was a member of the [Sigma Alpha Epsilon](https://www.edgepedia.org/sigma-alpha-epsilon) fraternity.[1](https://www.orbimed.com/leadership/w-carter-neild-cfa/) • [3](https://emory.academicworks.com/donors/carter-and-tania-neild) He later earned a C.E.P. from the Institut d'Etudes Politiques in Paris in 1991, his CFA charter in 1995, and an M.B.A. in Finance from the University of Chicago.[1](https://www.orbimed.com/leadership/w-carter-neild-cfa/) The Polsky Center lists him in the MBA class of 1997.[2](https://polsky.uchicago.edu/people/carter-neild/)
Before joining OrbiMed he was a Director in the UBS Alternative Investments Group and spent four years in the investment management division of First Chicago, which is now part of J.P. Morgan.[1](https://www.orbimed.com/leadership/w-carter-neild-cfa/)
He and his wife Tania endowed the Carter and Tania Hanford Neild Endowed Scholarship at Emory.[3](https://emory.academicworks.com/donors/carter-and-tania-neild)
## Role at OrbiMed
OrbiMed's leadership page states that Carter is a Managing Partner who joined the firm in 2002 and that he led OrbiMed's expansion in several areas, including healthcare royalty opportunities and Asia private investments.[1](https://www.orbimed.com/leadership/w-carter-neild-cfa/) The Polsky Center profile uses the same framing, describing OrbiMed as a $17 billion global healthcare-focused private investment firm and crediting Neild with growth in healthcare royalties and Asia private investments since 2002.[2](https://polsky.uchicago.edu/people/carter-neild/) The $17 billion figure comes from an undated university profile rather than a regulatory filing, so it should be read as an approximate, dated description of firm size rather than current assets under management.
## Fundraising and public commentary
In October 2023 OrbiMed closed more than $4 billion in fresh commitments across three funds, which PitchBook reported as the firm's largest venture and credit vehicles to date: a $1.86 billion US-focused ninth venture fund, a $1.71 billion royalties and credit vehicle, and a $751 million Asia-focused fifth venture and growth fund.[4](https://pitchbook.com/news/articles/ma-drug-discovery-hype-propel-orbimeds-43b-healthcare-fund-trio) PitchBook attributed the raise's momentum to a strong year of acquisitions in the pharmaceutical and biotech industries. The average check size for the ninth venture fund was expected to be around $50 million per company.[4](https://pitchbook.com/news/articles/ma-drug-discovery-hype-propel-orbimeds-43b-healthcare-fund-trio)
In the same article, Neild described the firm's positioning with institutional investors: "LPs are attracted to the fact that we're a really blue-chip institutional investment firm." He said OrbiMed's biggest limited partners are sovereign wealth funds and public pension schemes, and that more than 90% of the capital came from returning LPs.[4](https://pitchbook.com/news/articles/ma-drug-discovery-hype-propel-orbimeds-43b-healthcare-fund-trio)
## Public positions and recognition
Neild is a member of the Rockefeller University Council and the University of Chicago Booth Private Equity Council, according to OrbiMed's profile, and a member of the University of Chicago's Harper Society, according to the Polsky Center.[1](https://www.orbimed.com/leadership/w-carter-neild-cfa/) • [2](https://polsky.uchicago.edu/people/carter-neild/)
## References
1. [W. Carter Neild, CFA - OrbiMed](https://www.orbimed.com/leadership/w-carter-neild-cfa/)
2. [Carter Neild, MBA '97 - Polsky Center for Entrepreneurship and Innovation](https://polsky.uchicago.edu/people/carter-neild/)
3. [Carter and Tania Neild - Emory University Scholarships](https://emory.academicworks.com/donors/carter-and-tania-neild)
4. [Biopharma's M&A wave propels OrbiMed's $4.3B healthcare fund trio - PitchBook](https://pitchbook.com/news/articles/ma-drug-discovery-hype-propel-orbimeds-43b-healthcare-fund-trio)
---
*Topic: Encyclopedia › Society and history › Economics and business › Founders, operators, and investors › Venture and growth investors › Life-science venture and company creation › Biotech venture capital partners › Titles K to Z*
*Initially written Sep 17, 2026 · Edited: Oct 11, 2026; Oct 15, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license